Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jimmy-Lung: GME751 biosimilar versus EU-authorized Keytruda in untreated metastatic non-squamous NSCLC
jRCT2041240020Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of GME751 in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Hexal AG. Primary endpoint: Best overall response. Started Oct 2024; status: completed.
02
Drugs
GME751
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2041240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240020.